Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Zippelius

Showing results (131-140 of 163) with videos related to

Pageof 17
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 6, 2024
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage MelanomaKarlijn de Joode, Alfonso Rojas Mora, Ron H N van Schaik, et al.
Cell Reports. Medicine|April 12, 2023
N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancerPriska Auf der Maur, Marcel P Trefny, Zora Baumann, et al.
Immunity|December 19, 2024
The carbonyl nucleobase adduct M<sub>3</sub>Ade is a potent antigen for adaptive polyclonal MR1-restricted T cellsAndrew Chancellor, Daniel Constantin, Giuliano Berloffa, et al.
Nature|January 8, 2025
Precursors of exhausted T cells are pre-emptively formed in acute infectionTalyn Chu, Ming Wu, Barbara Hoellbacher, et al.
Journal for Immunotherapy of Cancer|November 1, 2022
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumorsMarina Natoli, Klas Hatje, Pratiksha Gulati, et al.
The Lancet. Oncology|November 6, 2015
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trialRolf A Stahel, Oliver Riesterer, Alexandros Xyrafas, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancerMarta Trüb, Franziska Uhlenbrock, Christina Claus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2019
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung CancerMarcel P Trefny, Sacha I Rothschild, Franziska Uhlenbrock, et al.
Journal for Immunotherapy of Cancer|November 17, 2024
Inhibition of Cbl-b restores effector functions of human intratumoral NK cellsSofia Tundo, Marcel Trefny, Andrijana Rodić, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLCKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Pageof 17

Showing results (131-140 of 163) with videos related to

Sort By:
Pageof 17
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 6, 2024
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage MelanomaKarlijn de Joode, Alfonso Rojas Mora, Ron H N van Schaik, et al.
Cell Reports. Medicine|April 12, 2023
N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancerPriska Auf der Maur, Marcel P Trefny, Zora Baumann, et al.
Immunity|December 19, 2024
The carbonyl nucleobase adduct M<sub>3</sub>Ade is a potent antigen for adaptive polyclonal MR1-restricted T cellsAndrew Chancellor, Daniel Constantin, Giuliano Berloffa, et al.
Nature|January 8, 2025
Precursors of exhausted T cells are pre-emptively formed in acute infectionTalyn Chu, Ming Wu, Barbara Hoellbacher, et al.
Journal for Immunotherapy of Cancer|November 1, 2022
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumorsMarina Natoli, Klas Hatje, Pratiksha Gulati, et al.
The Lancet. Oncology|November 6, 2015
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trialRolf A Stahel, Oliver Riesterer, Alexandros Xyrafas, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancerMarta Trüb, Franziska Uhlenbrock, Christina Claus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2019
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung CancerMarcel P Trefny, Sacha I Rothschild, Franziska Uhlenbrock, et al.
Journal for Immunotherapy of Cancer|November 17, 2024
Inhibition of Cbl-b restores effector functions of human intratumoral NK cellsSofia Tundo, Marcel Trefny, Andrijana Rodić, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLCKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Pageof 17